An open-label Phase I study to assess the safety of NKR-2 treatment administration after a non-myeloablative preconditioning chemotherapy in relapse/refractory acute myeloid leukemia or myelodysplastic syndrome patients

Brief description of study

If you have been diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), you may qualify for this Phase I study. The main goal of this study is to test the safety of a Chimeric Antigen Receptor Therapy (CAR-T) known as NKR-2 and understand how well NKR-2 works to destroy cancer cells in your body.


Clinical Study Identifier: s18-00159
ClinicalTrials.gov Identifier: NCT03466320
Principal Investigator: Ahmad S. Al-Homsi
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.